Co-Axet
ANTIBIOTICS: Cefuroxime Axetil & Clavulanic Acid
Indication
Pharyngitis or Tonsillitis, Acute bacterial maxillary sinusitis, Acute bacterial exacerbation of chronic bronchitis, Secondary bacterial infections of acute bronchitis, Community acquired pneumonia , Uncomplicated skin & skin-structure infections, MDR Typhoid fever, Uncomplicated urinary tract infection, Uncomplicated gonorrhea & Lyme disease.
Dosage & Administration
Pharyngitis or Tonsillitis : 250 mg twice daily for 5-10 days
Acute bacterial maxillary sinusitis : 250 mg twice daily for 10 days
Acute bacterial exacerbation of chronic bronchitis : 250-500 mg twice daily for 10 days
Secondary bacterial infections of acute bronchitis : 250-500 mg twice daily for 5-10 days
Community acquired pneumonia : 250-500 mg twice daily for 5-10 days
Uncomplicated skin & skin-structure infections : 250-500 mg twice daily for 10 days
MDR Typhoid fever : 500 mg twice daily for 10-14 days
Uncomplicated urinary tract infection : 250 mg twice daily for 7-10 days
Uncomplicated gonorrhea : 1000 mg once single dose
Lyme disease : 500 mg twice daily for 20 days
Co-Axet may be administered without regard to meals.
Side Effect
Generally Cefuroxime and Clavulanic Acid are well tolerated. However, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. Rarely (<0.2%) renal dysfunction, anaphylaxis, angioedema, pruritus, rash and serum sickness like urticaria may appear.
Precaution
Co-Axet should be given with care to patients receiving concurrent treatment with potent diuretics & who have history of colitis.
During pregnancy: While all antibiotics should be avoided in the first trimester if possible. However, Co-Axet can be safely used in later period of pregnancy to treat urinary and other infections.
During lactation: Co-Axet is excreted into the breast milk in small quantities. However, the possibility of sensitizing the infant should be kept in mind.
Drug Interaction
Concomitant administration of probenecid with Co-Axet increases the area under the serum concentration versus time curve by 50%. Drug that reduces gastric acidity may result in a lower bioavailability of Cefuroxime and tend to cancel the effect of postprandial absorption.
